Cargando…

Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism

IMPORTANCE: Extending the duration of oral anticoagulation for venous thromboembolism (VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear whether clinical outcomes differ when using direct oral anticoagulants (DOACs) or warfarin. OBJECTIVE: To compare rates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Margaret C., Reynolds, Kristi, Fan, Dongjie, Prasad, Priya A., Sung, Sue Hee, Portugal, Cecilia, Garcia, Elisha, Go, Alan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427945/ https://www.ncbi.nlm.nih.gov/pubmed/37581888 http://dx.doi.org/10.1001/jamanetworkopen.2023.28033

Ejemplares similares

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19
por: Fang, Margaret C., et al.
Publicado: (2023)

The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results
por: Portugal, Cecilia, et al.
Publicado: (2022)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

COVID-19 and Risk of VTE in Ethnically Diverse Populations
por: Go, Alan S., et al.
Publicado: (2021)

Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The SWAN Study
por: Hendriks, Thomas, et al.
Publicado: (2020)

Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19
por: Vaughn, Valerie M., et al.
Publicado: (2021)

Extended anticoagulation after venous thromboembolism: should it be done?
por: Fernandes, Caio J., et al.
Publicado: (2019)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants
por: Yanagisawa, Naohiro, et al.
Publicado: (2018)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2023)

Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
por: Weitz, Jeffrey I., et al.
Publicado: (2020)

Therapeutic options for the treatment of venous thromboembolism in case of warfarin intolerance: Effects of novel oral anticoagulants
por: Kodani, Eitaro
Publicado: (2013)

Recurrent Venous Thromboembolism in a Patient with Klippel-Trenaunay Syndrome Despite Adequate Anticoagulation with Warfarin
por: Asnake, Zekarias T, et al.
Publicado: (2020)

Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020
por: Iyer, Geetha S., et al.
Publicado: (2023)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding
por: Kang, Hye-Rim, et al.
Publicado: (2023)

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
por: Go, Alan S., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
por: Jun, Min, et al.
Publicado: (2017)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
por: Kang, Hye‐Rim, et al.
Publicado: (2023)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis
por: Niyomsri, Siwaporn, et al.
Publicado: (2023)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation
por: Schaefer, Jordan K., et al.
Publicado: (2022)

Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis
por: Mai, Vicky, et al.
Publicado: (2019)

Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
por: Park, Haesuk, et al.
Publicado: (2022)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
por: Witt, Daniel M., et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial
por: Ferro, José M., et al.
Publicado: (2019)

Association of Inferior Vena Cava Filter Placement for Venous Thromboembolic Disease and a Contraindication to Anticoagulation With 30-Day Mortality
por: Turner, Tyson E., et al.
Publicado: (2018)

Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism
por: Nemeth, Banne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l97qul8mjan3rhemis6gq7rjnm